This Program Project Grant application seeks support for translational clinical research studies to address some of the major obstacles to successful autologous and allogeneic hematopoietic cell transplantation (HCT) for hematologic malignancies. Thus, the overall goals of this grant are to: 1. To improve the long-term, disease-free survival of patients with hematological malignancy, 2. To extend the potential benefits of HCT to older patients with leukemia and lymphoma by the development of more effective and safer transplant regimens, 3. To translate previous laboratory observations in virology and tumor immunology made during the previous funding period into effective treatment strategies for patients undergoing HCT, and 4. To systematically delineate the short-term and long-term neurocognitive problems that afflict HCT recipients. This grant consists of four translational clinical projects and three cores. Project I entitled """"""""Radioimmunotherapy-based Transplant Regimens for Treatment of B-cell Lymphoma and Acute Myelogenous Leukemia"""""""" is focused on developing novel RIT-based preparative regimens in both the autologous and allogeneic with improved anti-tumor potency and tolerability and which can be tested in older patients with these diseases. Project II entitled """"""""Targeting Post-Transplant Minimal Residual CD19+ ALL with Genetically Modified CD19-specific T-cells,"""""""" will pilot adoptive therapy utilizing CD19-specific genetically-modified T cells as a strategy to target post-HCT minimal residual disease. In this project we also answer important questions about the immunobiology (in vivo expansion, homing and targeting to sites of disease) of donor-derived T-cell adoptive transfer in recipients of allogeneic T-cell depleted HCT for CD19+ ALL. Project III entitled """"""""Vaccine Induced Immunity to CMV"""""""", will test the first CMV vaccine intended for PBSC donors for augmenting transfer of CMV immunity to the patient with the goal of limiting post-HCT viremia. The investigators in this grant will be supported by three cores. The Administrative/Regulatory Affairs Core will oversee all administrative, financial, scientific review and data sharing for investigators in the grant and because seven of the trials will be conducted under institutionally-sponsored FDA INDs, Core A will also oversee the timely completion and submission of documents related to these INDs. Core B will continue to do data collection and management, and statistical analysis, and provide input into the design and publication of studies resulting from work in this grant. Core C will continue to provide long term follow-up and analysis of the recovery and health problems encountered by HCT-recipients treated on studies in this grant. In summary, the Program Project Grant renewal represents the ongoing, highly translational evolution of research by an integrated group of investigators focused on improving the outcome of HCT for patients with hematologic malignancies, and in particular, the first clinical applications of novel therapeutic interventions derived from laboratories in our program.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA030206-28
Application #
7844908
Study Section
Special Emphasis Panel (ZCA1-GRB-2 (O1))
Program Officer
Merritt, William D
Project Start
1997-04-01
Project End
2013-03-31
Budget Start
2010-07-13
Budget End
2013-03-31
Support Year
28
Fiscal Year
2010
Total Cost
$3,041,125
Indirect Cost
Name
City of Hope/Beckman Research Institute
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Limaye, Ajit P; La Rosa, Corinna; Longmate, Jeff et al. (2016) Plasma IL-10 Levels to Guide Antiviral Prophylaxis Prevention of Late-Onset Cytomegalovirus Disease, in High Risk Solid Kidney and Liver Transplant Recipients. Transplantation 100:210-6
Mardiros, Armen; Forman, Stephen J; Budde, Lihua E (2015) T cells expressing CD123 chimeric antigen receptors for treatment of acute myeloid leukemia. Curr Opin Hematol 22:484-8
Caruso, Hillary G; Hurton, Lenka V; Najjar, Amer et al. (2015) Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity. Cancer Res 75:3505-18
Israyelyan, A; Goldstein, L; Tsai, W et al. (2015) Real-time assessment of relapse risk based on the WT1 marker in acute leukemia and myelodysplastic syndrome patients after hematopoietic cell transplantation. Bone Marrow Transplant 50:26-33
Jonnalagadda, Mahesh; Mardiros, Armen; Urak, Ryan et al. (2015) Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacy. Mol Ther 23:757-68
Wang, Xiuli; Wong, ChingLam W; Urak, Ryan et al. (2015) CMVpp65 Vaccine Enhances the Antitumor Efficacy of Adoptively Transferred CD19-Redirected CMV-Specific T Cells. Clin Cancer Res 21:2993-3002
Wussow, Felix; Chiuppesi, Flavia; Martinez, Joy et al. (2014) Human cytomegalovirus vaccine based on the envelope gH/gL pentamer complex. PLoS Pathog 10:e1004524
Rushworth, David; Jena, Bipulendu; Olivares, Simon et al. (2014) Universal artificial antigen presenting cells to selectively propagate T cells expressing chimeric antigen receptor independent of specificity. J Immunother 37:204-13
Jena, Bipulendu; Moyes, Judy S; Huls, Helen et al. (2014) Driving CAR-based T-cell therapy to success. Curr Hematol Malig Rep 9:50-6
Singh, Harjeet; Huls, Helen; Kebriaei, Partow et al. (2014) A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19. Immunol Rev 257:181-90

Showing the most recent 10 out of 364 publications